However, currently available prognostic biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) show modest predictive power (8, 9). This evidence concerns the gene CD274 and neoplasm.